Skip to main content

UBS Group AG

Position in TRVI — Trevi Therapeutics, Inc.

CIK 1610520 ZURICH, V8

Position in TRVI

as of Mar 31, 2026 · filed May 5, 2026
Position Value
$5,323,069
+$1,884,728 QoQ
Shares Held
446,192
+62.5% QoQ
Ownership
0.314%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
21 quarters on record
Voting authority Sole 99.89376770538244.ToString("F0")% Shared 0.ToString("F0")% None 0.10623229461756376.ToString("F0")%

Common Shares in TRVI Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Mar 31, 2026

UBS Group AG holds $8,296,969,172 across 554 Biotechnology names. TRVI ranks #145 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in TRVI

Export CSV
21 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $5,323,069 446,192
2025-12-31 $3,438,341 274,628
2025-09-30 $2,732,298 298,612
2025-06-30 $1,937,610 354,225
2025-03-31 $585,177 93,033
2024-12-31 $187,521 45,515
2024-09-30 $93,059 27,862
2024-06-30 $53,666 18,009
2024-03-31 $145,307 42,118
2023-12-31 $42,045 31,377
2023-09-30 $49,213 22,575
2023-06-30 $57,491 24,055
2023-03-31 $14,023 7,580
2022-12-31 $5,965 3,091
2022-09-30 $6,586 4,277
2022-06-30 $13,406 4,771
2022-03-31 $3,572 1,624
2021-09-30 $7,242 5,173
2021-06-30 $4,808 2,137
2021-03-31 $6,444 2,378
2020-03-31 $1,779 541